Department of Clinical Laboratory, Fuding Hospital, Fujian University of Traditional Chinese Medicine, Fuding 355200, Fujian Province, China.
World J Gastroenterol. 2024 Nov 7;30(41):4411-4416. doi: 10.3748/wjg.v30.i41.4411.
This editorial offers an updated synthesis of the major advancements in the management and treatment of inflammatory bowel disease (IBD), as documented in the between 2023 and early 2024. This editorial explores substantial developments across key research areas, such as intestinal microecology, computational drug discovery, dual biologic therapy, telemedicine, and the integration of lifestyle changes into patient care. Furthermore, the discussion of emerging topics, including bowel preparation in colonoscopy, the impact of the coronavirus disease 2019 pandemic, and the intersection between IBD and mental health, reflects a shift toward a more holistic approach to IBD research. By integrating these diverse areas of research, this editorial seeks to promote a holistic and multidisciplinary approach to IBD treatment, combining emerging technologies, personalized medicine, and conventional therapies to improve patient outcomes.
本社论对 2023 年至 2024 年初期间发表的炎症性肠病(IBD)管理和治疗的主要进展进行了更新综合。本社论探讨了关键研究领域的重大进展,如肠道微生物组学、计算药物发现、双重生物治疗、远程医疗以及将生活方式改变纳入患者护理中。此外,对新兴主题的讨论,包括结肠镜检查中的肠道准备、2019 年冠状病毒病大流行的影响以及 IBD 与心理健康之间的交叉,反映了一种更全面的 IBD 研究方法的转变。通过整合这些不同的研究领域,本社论旨在促进 IBD 治疗的整体和多学科方法,结合新兴技术、个性化医学和常规疗法,以改善患者的治疗效果。